Bevacizumab

OUTLOOK ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Outlook To Contact Him Directly To Discuss Their Options

Retrieved on: 
Sunday, November 26, 2023
Agency, LLP, FDA, CMC, Court, News, Bevacizumab, Advertising, Safety, Woman, BLA, Cryptocurrency

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) and reminds investors of the January 2, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you purchased or acquired securities in Outlook between December 29, 2022 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • On August 30, 2023, Outlook issued a press release announcing that the FDA had issued a complete response letter to the ONS-5010 BLA.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Outlook’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

OTLK STOCK NEWS: Investors with Significant Losses in Outlook Therapeutics, Inc. Should Contact Robbins LLP for Information About the Outlook Therapeutics, Inc. Class Action

Retrieved on: 
Tuesday, November 21, 2023
Agency, Efficacy, LLP, FDA, CMC, AMD, Person, Complaint, SAN, Therapy, News, Viability, Bevacizumab, Safety, BLA

Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.

Key Points: 
  • Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • On August 30, 2023, Outlook issued a press release announcing that the FDA had issued a complete response letter (“CRL”) to the ONS-5010 BLA.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Outlook Therapeutics, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – OTLK

Retrieved on: 
Tuesday, November 21, 2023
Food, Agency, BLA, Outlook, LLP, FDA, Action Replay, CMC, Ext, AMD, Court, Person, Therapy, News, Complaint, Pomerantz, Bevacizumab, Prior, Safety, District court

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) and certain officers.

Key Points: 
  • NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

Retrieved on: 
Monday, November 20, 2023
MTD, Neurology, Neoplasm, PSTV, Index, IND, University of Texas System, Catheter, SNO, EBRT, Neuro-oncology, Plus, Neuro, Decompression (diving), MD, Doctor of Philosophy, Therapy, Clinical trial, Standard of care, CED, Society, Annual general meeting, Bevacizumab, MFD, Plus Therapeutics, NIH, Patient, University, Safety, Phase II, SOC, Radiation, KOL, Pharmaceutical industry

The Company is hosting a virtual key opinion leader (KOL) webinar to discuss the data today at 10:00 am ET.

Key Points: 
  • The Company is hosting a virtual key opinion leader (KOL) webinar to discuss the data today at 10:00 am ET.
  • Rhenium (186Re) obisbemeda continues to be generally safe and well tolerated, consistent with data accumulated in the Phase 1 trial.
  • Plus Therapeutics is hosting a virtual KOL event today, November 20, 2023 at 10:00 am ET to discuss the data presented at SNO.
  • A replay of the event will be available on Investor Relations section of the Plus Therapeutics website after the event.

Enterome’s OncoMimics™ Immunotherapy EO2401 Significantly Improves Survival Rate in Recurrent Glioblastoma

Retrieved on: 
Monday, November 20, 2023
Brain, FOXM1, Survival, SNO, Hope, Dana–Farber Cancer Institute, Progression-free survival, Service provider, Inflammation, Nivolumab, Society, Bevacizumab, Glioblastoma, Cancer, Patient, Harvard Medical School, PFS, Vaccine

PARIS, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced updated efficacy data from its Phase 1/2 clinical trial of EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab), for the treatment of patients with first progression/recurrence of glioblastoma (ROSALIE trial). The data were featured in an oral presentation at the Society for Neuro-Oncology (SNO) Annual Meeting, in Vancouver, British Columbia, Canada, on November 17th.

Key Points: 
  • The presentation entitled “EO2401 peptide immunotherapy + nivolumab +/- bevacizumab in first recurrent glioblastoma: the Phase 1/2 EOGBM1-18/ROSALIE study” was delivered by David Reardon, M.D., Professor of Medicine at Harvard Medical School and Clinical Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute.
  • “We are very pleased to present extensive data from the Phase 1/2 ROSALIE study of EO2401, our lead OncoMimics™ peptide-based immunotherapy, in glioblastoma,” said Pierre Belichard, Chief Executive Officer of Enterome.
  • The combination demonstrated encouraging results including a median survival of 14.5 months, median duration of response of 13.1 months, and median progression-free survival (PFS) of 5.5 months.
  • The survival rate of 57.4% and 43.1% was observed at 12 months and 18 months respectively.

OUTLOOK ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Outlook To Contact Him Directly To Discuss Their Options

Retrieved on: 
Sunday, November 19, 2023
Safety, BLA, Advertising, LLP, Bevacizumab, Woman, Agency, FDA, CMC, Court, News, Cryptocurrency, Outlook

NEW YORK, Nov. 19, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) and reminds investors of the January 2, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you purchased or acquired securities in Outlook between December 29, 2022 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • On August 30, 2023, Outlook issued a press release announcing that the FDA had issued a complete response letter to the ONS-5010 BLA.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Outlook’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 16, 2023
Colorectal cancer, Dicarboxylic acid, Bevacizumab, Patient, Part, NCNA, Therapy, Lung cancer, Melanoma, Survival, Immunotherapy, Irinotecan, Docetaxel, Oxaliplatin, Cryptocurrency, Pharmaceutical industry

EDINBURGH, United Kingdom, Nov. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2023 and provided an update on its broad clinical development program with its transformative ProTide therapeutics.

Key Points: 
  • EDINBURGH, United Kingdom, Nov. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2023 and provided an update on its broad clinical development program with its transformative ProTide therapeutics.
  • As of September 30, 2023, NuCana had cash and cash equivalents of £17.8 million compared to £24.6 million at June 30, 2023 and £41.9 million at December 31, 2022.
  • NuCana continues to advance its various clinical programs and reported a net loss of £6.7 million for the quarter ended September 30, 2023, as compared to a net loss of £4.5 million for the quarter ended September 30, 2022.
  • Basic and diluted loss per share was £0.13 for the quarter ended September 30, 2023, as compared to £0.09 per share for the comparable quarter ended September 30, 2022.

OUTLOOK SHAREHOLDER ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Outlook To Contact Him Directly To Discuss Their Options

Retrieved on: 
Tuesday, November 14, 2023
Safety, BLA, Advertising, LLP, Bevacizumab, Woman, Agency, FDA, CMC, Court, News, Cryptocurrency, Outlook

NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) and reminds investors of the January 2, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you purchased or acquired securities in Outlook between December 29, 2022 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • On August 30, 2023, Outlook issued a press release announcing that the FDA had issued a complete response letter to the ONS-5010 BLA.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Outlook’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe

Retrieved on: 
Tuesday, November 14, 2023
Ophthalmology, Senior, Therapy, Royal college, Bevacizumab, MAA, Outlook, University College Dublin, EMA, ADHD, FDA, Marketing, Partnership, AMD, Doctor of Philosophy, Market access, Retina, Pharmaceutical industry, Chemistry, Science

ISELIN, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced the appointment of Jedd Comiskey as Senior VP – Head of Europe.

Key Points: 
  • ISELIN, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced the appointment of Jedd Comiskey as Senior VP – Head of Europe.
  • Mr. Comiskey has a successful track record in the planning, organization and execution of product launches.
  • Over the course of his career, he has demonstrated innovative, solution-focused results, navigating the highly complex European pharmaceutical landscape.
  • “We believe in the potential of ONS-5010 to address the global need for an approved bevacizumab that meets ophthalmic standards for the treatment of wet AMD.

OTLK Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in the Outlook Therapeutics, Inc. Class Action

Retrieved on: 
Monday, November 13, 2023
Safety, SAN, Efficacy, Therapy, BLA, LLP, Bevacizumab, Complaint, Viability, Agency, FDA, Person, AMD, CMC, News, Inc.

Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.

Key Points: 
  • Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Outlook Therapeutics, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.